HEY/17/062 CONTRAST MEDIA
Hull University Teaching Hospitals NHS TrustcontractFind a Tender ↗Ref ocds-h6vhtk-028e0632014L0024active
Estimated value
—
goods
Awarded value
—
Suppliers
15
2 SME
Lots
12
12 awarded
Published
28 Jan 2021
Description
For the supply and deliver of contrast media
Scope
- Reference
- DN284390
- Commercial tool
- Standalone contract
- Main category
- goods
- CPV classifications
- 33000000
- Contract locations
- Yorkshire and the HumberYorkshire and the Humber
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Clinical Suitability – viscosity of the contrast agent [AC2] | 12 | quality | — |
| Cardiac Labs Specific [AC3] | 8 | quality | — |
| Continuity of Supply [AC4] | 8 | quality | — |
| Product Assessment [AC5] | 25 | quality | — |
| Delivery / timescale / implementation proposals [AC6] | 5 | quality | — |
| Added value/Innovative procurement [AC7] | 2 | quality | — |
| Contingency planning [AC8] | 5 | quality | — |
| Whole life costs [AC1] | 30 | cost | — |
| Sustainability [AC9] | 3 | cost | — |
| Ethical issues [AC10] | 2 | cost | — |
| Contrast agent for patients younger than two years of age [AC2] | 8 | quality | — |
| Published Safety data [AC3] | 8 | quality | — |
| Injector Pump Compatibility [AC4] | 5 | quality | — |
| Continuity of Supply [AC5] | 7 | quality | — |
| Product Assessment [AC6] | 25 | quality | — |
| Delivery / timescale / implementation proposals [AC7] | 5 | quality | — |
| Added value/Innovative procurement [AC8] | 3 | quality | — |
| Contingency planning [AC9] | 3 | quality | — |
| Sustainability [AC10] | 3 | quality | — |
| Ethical issues [AC11] | 3 | quality | — |
| Published Safety data [AC2] | 10 | quality | — |
| Injector Pump Compatibility [AC3] | 5 | quality | — |
| Continuity of Supply [AC4] | 7 | quality | — |
| Product Assessment [AC5] | 26 | quality | — |
| Delivery / timescale / implementation proposals [AC6 | 5 | quality | — |
| Added value/Innovative procurement [AC7] | 4 | quality | — |
| Sustainability [AC9] | 4 | quality | — |
| Ethical issues [AC10] | 4 | quality | — |
| Contrast Media CT - IV use, availability of variety of strengths [AC2] | 5 | quality | — |
| Contrast Media CT - IV use, available in variety of vial sizes [AC3] | 5 | quality | — |
| Continuity of Supply [AC4] | 5 | quality | — |
| CT Devices - Contrast media followed by saline [AC5] | 10 | quality | — |
| Delivery / timescale / implementation proposals [AC6] | 3 | quality | — |
| Ability to provide and proposals for upgradeability/future-proofing of the devices [AC7] | 3 | quality | — |
| Product Assessment [AC8] | 25 | quality | — |
| Quality of Service Maintenance support offered fully comprehensive and PPM, including technical support arrangements [AC9] | 5 | quality | — |
| Initial and on-going training. (CT Devices) [AC10] | 3 | quality | — |
| Contingency planning [AC11] | 2 | quality | — |
| Sustainability [AC12] | 2 | quality | — |
| Ethical issues [AC13] | 2 | quality | — |
| Contrast Media CT – Oral contrast, availability of variety of strengths [AC2] | 8 | quality | — |
| Contrast Media CT – Oral contrast, availability of variety of sizes [AC3] | 10 | quality | — |
| Product advances [AC5] | 4 | quality | — |
| Delivery / timescale / implementation proposals [AC6] | 8 | quality | — |
| Product Assessment [AC7] | 20 | quality | — |
| Contrast Media CT – CTC oral contrast agent suitable for faecal tagging, availability of variety of sizes [AC2] | 10 | quality | — |
| Continuity of Supply [AC3] | 10 | quality | — |
| Product advances [AC4] | 3 | quality | — |
| Delivery / timescale / implementation proposals [AC5] | 10 | quality | — |
| Added value/Innovative procurement [AC7] | 3 | quality | — |
| Contingency planning [AC8] | 3 | quality | — |
| Sustainability [AC9] | 3 | quality | — |
| Ethical issues [AC10] | 3 | cost | — |
| Contrast Media CT – Is the product a high-osmolality contrast agent [AC2] | 10 | quality | — |
| Ethical issues [AC10] | 3 | quality | — |
| Clinical Suitability – viscosity of the contrast agent [AC2] | 15 | quality | — |
| Disposed of in a cost effective way [AC3] | 2 | quality | — |
| Continuity of Supply [AC4] | 10 | quality | — |
| Contingency planning [AC8] | 4 | quality | — |
| Sustainability [AC9] | 2 | quality | — |
| Ethical issues [AC10] | 2 | quality | — |
| General Radiology for use in Gastro-Intestinal Imaging, availability of variety of sizes [AC2] | 15 | quality | — |
| Delivery / timescale / implementation proposals [AC5] | 8 | quality | — |
| Clinical Suitability – viscosity of the contrast agent [AC2] | 10 | quality | — |
| Reconstituted prior to administration [AC3] | 5 | quality | — |
| Contrast agents are safe with a very low incidence of side effects [AC4] | 10 | quality | — |
| Bottle Disposal [AC5] | 3 | quality | — |
| Continuity of Supply [AC6] | 5 | quality | — |
| Product Assessment [AC7] | 17 | quality | — |
| Delivery / timescale / implementation proposals [AC8] | 8 | quality | — |
| Added value/Innovative procurement [AC9] | 4 | quality | — |
| Contingency planning [AC10] | 4 | quality | — |
| Sustainability [AC11] | 2 | quality | — |
| Ethical issues [AC12] | 2 | quality | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 12 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 12 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | LOT 1 - CONTRAST MEDIA FOR CARDIAC LABS AND INTERVENTIONAL RADIOLOGY | — | cancelled |
| 2.1 | General MRI contrast agent for head/whole body/ musculo-skeletal and paediatrics | — | cancelled |
| 2.2 | MRI contrast agent for angio and cardiac | — | cancelled |
| 2.3 | MRI contrast agent for intra-articular | — | cancelled |
| 2.4 | MRI contrast agent for liver | — | cancelled |